The integration of generative artificial intelligence (GenAI) into the life sciences industry is revolutionizing drug discovery by offering enhanced capabilities across various stages of the process. However, this technological advancement also brings forth complex legal challenges. As organizations strive to leverage GenAI for its potential benefits, they must address pivotal legal, regulatory, and practical considerations to ensure compliance within this evolving landscape.
Ensuring legal compliance when deploying GenAI technologies involves navigating existing regulations while preparing for new policies that may arise as the field grows. The attorneys at Sullivan & Cromwell highlight the necessity for companies to stay informed about emerging best practices, as regulatory frameworks could shift in response to technological advances in GenAI. These insights come as part of a broader discussion featured in an article on Law360, which delves into the intricacies of legal compliance in the context of GenAI in life sciences.